MediPharm Labs Enters Denmark Healthcare Cannabis Industry, Secures New White-Label Provide Shoppers

bunch of red fruits

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, study-driven pharmaceutical-high quality cannabis extraction, distillation and derivative items, currently announced it will provide cannabis concentrate items in Denmark to two new health-related cannabis consumers below two separate white-label agreements. These consumers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ 1st provide agreements for the export of completed items to Denmark.

Denmark granted individuals legal access to cannabis-primarily based medicinal items two years ago as component of a 4-year pilot plan. The plan delivers individuals with secure item access and national overall health authorities with patient information that they can use to comprehend usage and efficacy. According to details complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mainly girls amongst the ages of 42-64) received cannabis-primarily based medicinal items from 429 prescribing medical doctors below this plan in 2019.

“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent a different step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related marketplace with new and revolutionary health-related cannabis focused items positions us for further development in Europe and adds to MediPharm Labs all-essential physique of information that we are leveraging to boost the style of our formulations for individuals and shoppers everywhere.”

Beneath the agreements, a single which has an initial two-year term and the second a a single-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil items that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its consumers to start in October 2020, pending regulatory approval by applicable overall health authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured many incredibly eye-catching domestic and international provide agreements with higher high quality partners, now like new consumers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new business enterprise wins are a clear and essential validation of our selection to make a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs expanding profile and reputation. We appear forward to ramping up production below all of these agreements.”

MediPharm Labs Australia received its Fantastic Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Could 2020, which enables it to sell cannabis APIs and completed items to nations across the EU, like Denmark. The Enterprise entered into its 1st European white-label cannabis provide agreement that very same month with Therismos Restricted.

About Denmark’s Healthcare Cannabis Industry

Denmark launched its 4-year health-related cannabis pilot plan on January 1st, 20181. Post-harvest Fantastic Manufacturing Processes (GMP) is needed for distribution of health-related cannabis items in Denmarktwo.

Via the plan, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 regions: discomfort brought on by numerous sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an substantial critique of literature as nicely as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high quality cannabis oil and concentrates and sophisticated derivative items using a Fantastic Manufacturing Practices certified facility with ISO typical constructed clean rooms. MediPharm Labs has invested in an specialist, study-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 major extraction lines for delivery of pure, trusted and precision -dosed cannabis items for its consumers. Via its wholesale and white label platforms, they formulate, customer-test, course of action, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based items to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional details, please make contact with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E mail: [email protected]
Web page: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot System. Retrieved: https://laegemiddelstyrelsen.dk/en/specific/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Healthcare Cannabis Industry in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-health-related-cannabis-marketplace-in-denmark-europe/80721/
three The Danish Healthcare Cannabis Pilot Programme: Placing the Patient Initial. Retrieved: https://www.healtheuropa.eu/the-danish-health-related-cannabis-pilot-programme-placing-the-patient-1st/92991/

CAUTIONARY NOTE With regards to FORWARD-Seeking Details:

This news release includes “forward-searching information” and “forward-searching statements” (collectively, “forward-searching statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-searching statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that entails discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (generally but not constantly working with phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or outcomes “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical truth and may well be forward-searching statements. In this news release, forward-searching statements relate to, amongst other factors, the prosperous overall performance of the agreements and shipping of items thereunder as planned further development in Europe and enhancing the style of formulations. Forward-searching statements are necessarily primarily based upon a quantity of estimates and assumptions that, whilst regarded as affordable, are topic to identified and unknown dangers, uncertainties, and other things which may well trigger the actual outcomes and future events to differ materially from these expressed or implied by such forward-searching statements. Such things contain, but are not restricted to: basic business enterprise, financial, competitive, political and social uncertainties the inability of MediPharm Labs to get sufficient financing the delay or failure to acquire regulatory approvals and other things discussed in MediPharm Labs’ filings, out there on the SEDAR web-site at www.sedar.com. There can be no assurance that such statements will prove to be correct, as actual outcomes and future events could differ materially from these anticipated in such statements. Accordingly, readers ought to not location undue reliance on the forward-searching statements and details contained in this news release. Except as needed by law, MediPharm Labs assumes no obligation to update the forward-searching statements of beliefs, opinions, projections, or other things, ought to they transform.

Primary Logo

If You Liked This Report Click To Share

.mobile_tx{show: none}
#ax1x{
font-size: 1.1em
font-weight: bold
line-height: 1.five
clear:each
margin: 0px 0px 20px 1% !essential
min-height: four.5em
text-transform: uppercase
padding: .25em 10px
position: relative
width: 98%
float: left
}
.subsequent-pg {
height: 85px !essential
width: one hundred%
border-major-left-radius: 3px
border-bottom-left-radius: 3px
background-colour: #e5192c
background-image: url(‘/wp-content material/themes/mh-magazine/photos/worldwide-soon after.png’) !essential
background-repeat: no-repeat
background-position: proper center
background-size: auto one hundred%
overflow: hidden
box-sizing: border-box
margin-bottom: 0px
margin-major: 10px
position: relative
padding-left: 100px
}
.subsequent-pg::just before {
width: 45px !essential
height: 85px !essential
show: block
content material: “”
width: 32px
height: 64px
background-image: url(‘/wp-content material/themes/mh-magazine/photos/worldwide-just before.png’) !essential
background-repeat: no-repeat
background-position: proper center
background-size: auto one hundred%
position: absolute
left: -4px
major: 0px
}
.action-txt {
text-transform: uppercase
margin: 12px
line-height: 61px
text-align: left
font-size: 36px
background-repeat: no-repeat
background-position: proper center
background-size: 26px 18px
colour: #FFF
float: left
font-weight: bold
font-household: “Open Sans”,sans-serif !essential
width: 78%
show: inline-block
text-align: center
}
@media (max-width: 768px){
.mobile_tx{show: block}
.desktop_tx{show: none}
.pps-slider-nav .pps-subsequent {
text-align: center
position: static
padding: 5px 20px
float: left
width: one hundred%
box-sizing: border-box
}
.pps-subsequent .subsequent-report-web page {
padding-left:
float: left
margin:
}
.subsequent-report-web page .action-txt {
padding-left: !essential
text-align: center
width: 87%
box-sizing: border-box
font-size: 26px
background:
text-align: center
}
#ax1x {
padding: .25em !essential
min-height: two.3em
width: one hundred% !essential
margin: 0px !essential
margin-bottom: 15px !essential
padding-bottom: !essential
}
}
@media (max-width: 500px){
.subsequent-report-web page .action-txt{
width: 75%
}
}

Latest posts